denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Description:
Women face unique haemostatic and thrombotic challenges during their life relating mainly to menstruation and pregnancy and childbirth. In women with inherited or acquired bleeding disorders these events can be even more challenging. These important clinical issues are often overlooked and underestimated in clinical practice and clinical research but in recent years it is gratifying that attention is being directed to them. This educational session will use clinical case studies to explore and discuss issues to identify best practice for assessing and managing clinical bleeding issues in women with inherited or acquired bleeding disorders and identify areas for future research to continue to improve care.
Dr Paula James will explore the significant barriers faced by women with bleeding disorders in terms of recognition and attention to their symptoms. It has been reported that women can wait up to 15 years from the onset of bleeding symptoms to an accurate diagnosis. Barriers include lack of recognition of normal vs. abnormal bleeding (especially gynecologic and obstetric), challenges in terms of laboratory testing and issues around disease classification and nomenclature. Efforts to raise awareness about the challenges facing women with bleeding disorders will be discussed as will international efforts to improve diagnosis and access to care.
Dr Bethany Samuelson Bannow will review the incidence of heavy menstrual bleeding as a complication of anticoagulation in menstruating women. She will discuss mainstays of therapy including hormonal therapies, procedure-based interventions and supportive care, as well as iron supplementation. She will review the impact of approaches including modifying the duration of anticoagulation or skipping doses and switching oral anticoagulants.
Dr Claire McLintock will review the risk factors, prevalence and management of postpartum hemorrhage (PPH). She will specifically address emerging evidence directing changes in the management of women with PPH highlighting the importance of rapid identification of women with low fibrinogen levels who require urgent fibrinogen replacement as well as optimal transfusion practice. She will also review the evidence relating to tranexamic acid in treatment of PPH.
Dr Paula James will explore the significant barriers faced by women with bleeding disorders in terms of recognition and attention to their symptoms. It has been reported that women can wait up to 15 years from the onset of bleeding symptoms to an accurate diagnosis. Barriers include lack of recognition of normal vs. abnormal bleeding (especially gynecologic and obstetric), challenges in terms of laboratory testing and issues around disease classification and nomenclature. Efforts to raise awareness about the challenges facing women with bleeding disorders will be discussed as will international efforts to improve diagnosis and access to care.
Dr Bethany Samuelson Bannow will review the incidence of heavy menstrual bleeding as a complication of anticoagulation in menstruating women. She will discuss mainstays of therapy including hormonal therapies, procedure-based interventions and supportive care, as well as iron supplementation. She will review the impact of approaches including modifying the duration of anticoagulation or skipping doses and switching oral anticoagulants.
Dr Claire McLintock will review the risk factors, prevalence and management of postpartum hemorrhage (PPH). She will specifically address emerging evidence directing changes in the management of women with PPH highlighting the importance of rapid identification of women with low fibrinogen levels who require urgent fibrinogen replacement as well as optimal transfusion practice. She will also review the evidence relating to tranexamic acid in treatment of PPH.